2023
Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
Lebwohl M, Egeberg A, Linaberry M, Hoyt K, Banerjee S, Kisa R, Strober B. Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program. SKIN The Journal Of Cutaneous Medicine 2023, 7: s116. DOI: 10.25251/skin.7.supp.116.Peer-Reviewed Original ResearchSevere plaque psoriasisAlanine aminotransferasePlaque psoriasisConcomitant medicationsWeeks 0Week 16Multiple laboratory parametersCommon Terminology CriteriaMean levelsTreatment of adultsWeeks of treatmentPatient-level dataOral placeboTerminology CriteriaAST elevationLiver transaminasesAminotransferase levelsCTCAE gradeLiver dysfunctionSystemic therapyLaboratory parametersAST levelsTreatment armsLiver conditionsSeverity grade
2022
POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
Fleischmann R, Thaçi D, Gooderham M, Strober B, Korman N, Banerjee S, Lehman T, Nowak M, Sreih A, Morita A, Mease P. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS. Annals Of The Rheumatic Diseases 2022, 81: 835.2-836. DOI: 10.1136/annrheumdis-2022-eular.1862.Peer-Reviewed Original ResearchConcomitant conventional synthetic DMARDsPhase 2 trialGrant/research supportKyowa Hakko KirinBristol-Myers SquibbCommon Terminology CriteriaPhase 3 trialSanofi GenzymeWeeks of treatmentLaboratory parametersPsoriatic arthritisLEO PharmaBoehringer IngelheimSun Pharmaceutical IndustriesUCB PharmaSpeaker feesNippon KayakuPlacebo nPsA trialsPsoriasis RegistryTerminology CriteriaWk 1Eli LillyLarge phase 3 trialsMitsubishi Tanabe